Developing new antibiotic combinations to fight resistant infections.
Innovative technologies to transform antibiotic discovery. Project 2 Engineering antibiotic sensitization therapies
This study is looking for better ways to treat tough infections caused by germs like Klebsiella pneumoniae by testing different combinations of antibiotics, so patients can have more effective treatments and recover faster.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10670189 on NIH RePORTER |
What this research studies
This research focuses on creating innovative therapies to combat multidrug-resistant infections caused by ESKAPE pathogens, particularly Klebsiella pneumoniae. By exploring combinations of existing antibiotics, the project aims to enhance their effectiveness and reduce the likelihood of drug resistance. The approach involves sophisticated experimental and analytical methods to evaluate how different drugs interact with each other, allowing researchers to identify the most effective combinations for treating these challenging infections. Patients may benefit from more effective treatment options that can lead to quicker recovery and reduced complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from infections caused by multidrug-resistant ESKAPE pathogens, particularly those with Klebsiella pneumoniae.
Not a fit: Patients with infections caused by non-ESKAPE pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective antibiotic treatments that can overcome drug resistance.
How similar studies have performed: Other research has shown promise in using combination therapies to combat antibiotic resistance, indicating that this approach has potential for success.
Where this research is happening
Cambridge, United States
- Broad Institute, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Blainey, Paul Clark — Broad Institute, INC.
- Study coordinator: Blainey, Paul Clark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.